Patents Assigned to AbbVie Inc.
  • IL-17 BINDING PROTEINS
    Publication number: 20140343267
    Abstract: Proteins that bind IL-17 and/or IL-17F are described along with there use in composition and methods for treating, preventing, and diagnosing IL-17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions.
    Type: Application
    Filed: April 24, 2014
    Publication date: November 20, 2014
    Applicant: ABBVIE INC.
    Inventors: Chung-Ming Hsieh, Margaret Hugunin, Anwar Murtaza, Bradford L. McRae, Yuliya Kutskova, John E. Memmott, Jennifer M. Perez, Suju Zhong, Edit Tarcsa, Anca Clabbers, Craig Wallace, Shaughn H. Bryant, Mary R. Leddy
  • METHODS AND COMPOSITIONS FOR TREATING ASTHMA USING ANTI-IL-13 ANTIBODIES
    Publication number: 20140341913
    Abstract: The invention provides methods and compositions for treating asthma, e.g., mild or moderate asthma, in a subject using an anti-IL-13 antibody, or antigen-binding portion thereof.
    Type: Application
    Filed: July 2, 2012
    Publication date: November 20, 2014
    Applicant: ABBVIE INC.
    Inventor: Catherine Tripp
  • Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
    Patent number: 8889675
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.
    Type: Grant
    Filed: October 11, 2012
    Date of Patent: November 18, 2014
    Assignee: AbbVie Inc.
    Inventors: Le Wang, George Doherty, Xilu Wang, Zhi-Fu Tao, Milan Bruncko, Aaron R. Kunzer, Michael D. Wendt, Xiaohong Song, Robin Frey, Todd M. Hansen, Gerard M. Sullivan, Andrew Judd, Andrew Souers
  • Treatment of osteoarthritis and pain
    Patent number: 8889130
    Abstract: The present invention relates to the treatment of osteoarthritis and pain using IL-1? and IL-1? binding proteins, including anti-IL-1? and anti-IL-1? antibodies and engineered multivalent and multispecific IL-1? and IL-1? binding proteins.
    Type: Grant
    Filed: February 8, 2012
    Date of Patent: November 18, 2014
    Assignee: Abbvie Inc.
    Inventor: Rajesh V. Kamath
  • NAMPT INHIBITORS
    Publication number: 20140336167
    Abstract: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.
    Type: Application
    Filed: May 10, 2013
    Publication date: November 13, 2014
    Applicant: ABBVIE INC.
    Inventors: Ramzi F. Sweis, Michael L. Curtin, Marina A. Pliushchev, Todd M. Hansen, Kenton Longenecker
  • IL-17 BINDING PROTEINS
    Publication number: 20140335564
    Abstract: Proteins that bind IL-17 and/or IL-17F are described along with there use in composition and methods for treating, preventing, and diagnosing IL-17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions.
    Type: Application
    Filed: April 22, 2014
    Publication date: November 13, 2014
    Applicant: ABBVIE INC.
    Inventors: Chung-Ming Hsieh, Margaret Hugunin, Anwar Murtaza, Bradford L. McRae, Yuliya Kutskova, John E. Memmott, Jennifer M. Perez, Suju Zhong, Edit Tarcsa, Anca Clabbers, Craig Wallace, Shaughn H. Bryant, Mary R. Leddy
  • IL-1 ALPHA DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF
    Publication number: 20140335014
    Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
    Type: Application
    Filed: April 8, 2014
    Publication date: November 13, 2014
    Applicant: AbbVie, Inc.
    Inventors: Tariq Ghayur, Peter C. Isakson, Lisa M. Olson, Chengbin Wu, Margaret Hugunin, Rajesh V. Kamath, Carolyn A. Cuff, Hamish Allen
  • Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
    Patent number: 8883784
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.
    Type: Grant
    Filed: August 12, 2013
    Date of Patent: November 11, 2014
    Assignee: AbbVie Inc.
    Inventors: Andrew S. Judd, Andrew J. Souers, Zhi-Fu Tao
  • Protein formulations and methods of making same
    Patent number: 8883146
    Abstract: The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductity resulting from the low levels of ionic excipients. Also included in the invention are formulations comprising water and proteins having low osmolality.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: November 11, 2014
    Assignee: AbbVie Inc.
    Inventors: Wolfgang Fraunhofer, Annika Bartl, Hans-Juergen Krause, Markus Tschoepe, Katharina Kaleta
  • TNF-? binding proteins
    Patent number: 8877194
    Abstract: TNF-? binding proteins, including chimeric, CDR-grafted, and humanized antibodies that bind TNF-? are provided. Binding proteins have high affinity for TNF-? and neutralize TNF-? activity. A binding protein can be a full-length antibody or a TNF-?-binding portion thereof. Methods of making and methods of using the binding proteins are also described. The TNF-? binding proteins are useful for detecting TNF-? and for inhibiting TNF-? activity, including in a human subject suffering from a disease or disorder in which TNF-? activity is detrimental.
    Type: Grant
    Filed: December 8, 2011
    Date of Patent: November 4, 2014
    Assignee: AbbVie Inc.
    Inventors: Chung-ming Hsieh, Carrie L. Goodreau, Sahana Bose, Achim Moeller, Tariq Ghayur
  • A? conformer selective anti-A? globulomer monoclonal antibodies
    Patent number: 8877190
    Abstract: The subject invention relates to monoclonal antibodies that may be used in the treatment and diagnosis of Alzheimer's Disease. In particular, the present invention relates to monoclonal antibodies referred to as 10F4 and 3C5 and to other monoclonal antibodies (e.g., murine, human or humanized) having similar properties thereto.
    Type: Grant
    Filed: May 6, 2011
    Date of Patent: November 4, 2014
    Assignees: AbbVie Inc., AbbVie Deutschland GmbH & Co. KG
    Inventors: Stefan Barghorn, Heinz Hillen, Andreas R. Striebinger, Boris Labkovsky, Ulrich Ebert, Patrick Keller
  • Polynucleotides encoding humanized anti-NGF antibodies
    Patent number: 8877491
    Abstract: Method for the humanization of the VH and VL variable regions of an animal antibody of known sequence, humanized animal antibody obtainable according to the method, in particular anti-NGF and anti-TrkA humanized animal antibodies.
    Type: Grant
    Filed: July 16, 2010
    Date of Patent: November 4, 2014
    Assignee: Abbvie Inc.
    Inventors: Antonino Cattaneo, Doriano Lamba, Sonia Covaceuszach
  • TRPA1 antagonists
    Patent number: 8877784
    Abstract: Compounds of formula (I) wherein R1, R2, R3, and Y are defined in the description are TRPA1 antagonists. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
    Type: Grant
    Filed: January 2, 2009
    Date of Patent: November 4, 2014
    Assignee: Abbvie Inc.
    Inventors: Richard J. Perner, Michael E. Kort, Stanley DiDomenico, Jun Chen, Anil Vasudevan
  • 11-?-hydroxysteroid dehydrogenase type 1 (11?-HSD1) inhibitors and uses thereof
    Patent number: 8871208
    Abstract: A method for treating a patient suffering from inflammation, chronic inflammation, pain, rheumatoid arthritis (RA), osteoarthritis and osteoporosis, comprising administering an effective amount of a selective inhibitor of the 11-?-hydroxysteroid dehydrogenase Type 1 enzyme.
    Type: Grant
    Filed: December 2, 2010
    Date of Patent: October 28, 2014
    Assignee: AbbVie Inc.
    Inventors: Peer B. Jacobson, Lisa M. Olson, Sreeinvasarao Vepachedu
  • METHODS TO CONTROL PROTEIN HETEROGENEITY
    Publication number: 20140314745
    Abstract: The instant invention relates to the field of protein production and in particular to controlled protein heterogeneity compositions and processes for controlling the heterogeneity of proteins expressed in host cells.
    Type: Application
    Filed: February 28, 2014
    Publication date: October 23, 2014
    Applicant: ABBVIE INC.
    Inventors: Lisa M. Rives, Cornelia Bengea, Xiaobei Zeng
  • 6H-IMIDAZO[1,5-a]PYRROLO[2,3-e]PYRAZINE COMPOUNDS
    Publication number: 20140315883
    Abstract: The invention provides a compound of Formula (I as defined herein, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Application
    Filed: April 18, 2014
    Publication date: October 23, 2014
    Applicant: ABBVIE INC.
    Inventors: Eric Breinlinger, Heather Davis, Michael Hoemann, Bin Li, Biqin Li, Gagandeep Somal, Stacy Van Epps, Lu Wang, Lu Wang
  • Methods of treatment using human antibodies that bind IL-12
    Patent number: 8865174
    Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
    Type: Grant
    Filed: March 12, 2012
    Date of Patent: October 21, 2014
    Assignee: AbbVie Inc.
    Inventors: Jochen G. Salfeld, Michael Roguska, Michael Paskind, Subhashis Banerjee, Daniel Edward Tracey, Michael White, Zehra Kaymakcalan, Boris Labkovsky, Paul Sakorafas, Geertruida M. Veldman, Amy Venturini, Angela Widom, Stuart Friedrich, Nicholas W. Warne, Angela Kantor, John Gawain Elvin, Alexander Robert Duncan, Elaine J. Derbyshire, Sara Carmen, Stephen Smith, Thor Las Holtet, Sarah Leila Du Fou
  • Compounds as cannabinoid receptor ligands
    Patent number: 8865753
    Abstract: The present application relates to thiazolylidene containing compounds of formula (I) wherein R1, R2, R3, R4, L2 and A are as defined in the specification. Compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
    Type: Grant
    Filed: December 16, 2010
    Date of Patent: October 21, 2014
    Assignee: AbbVie Inc.
    Inventors: Teodozyj Kolasa, Jennifer M. Frost, Meena V. Patel, Steven P. Latshaw, Arturo Perez-Medrano, Xueqing Wang, Sridhar Peddi, William A. Carroll, Michael J. Dart
  • DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF
    Publication number: 20140308286
    Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
    Type: Application
    Filed: March 19, 2014
    Publication date: October 16, 2014
    Applicant: AbbVie Inc.
    Inventors: Tariq Ghayur, Jochen G. Salfeld, Michael J. McPherson, Maria C. Harris, Junjian Liu, Peter C. Isakson, Jijie Gu
  • Potassium channel modulators
    Patent number: 8859549
    Abstract: Disclosed herein are KCNQ potassium channels modulators of formula (I) wherein ring G1, R1, and R2 are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using such compounds and compositions are also described.
    Type: Grant
    Filed: May 8, 2012
    Date of Patent: October 14, 2014
    Assignee: AbbVie, Inc.
    Inventors: Brian S. Brown, Tongmei Li, Sridhar Peddi, Arturo Perez-Medrano, David DeGoey